Cargando…

The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo

A phase 2 clinical trial investigating the efficacy and safety of AS602801, a newly developed JNK inhibitor, in the treatment of inflammatory endometriosis is complete. We are now examining whether AS602801 acts against human cancer cells in vitro and in vivo. In vitro, AS602801 exhibited cytotoxici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Masashi, Kuramoto, Kenta, Takeda, Hiroyuki, Watarai, Hikaru, Sakaki, Hirotsugu, Seino, Shizuka, Seino, Manabu, Suzuki, Shuhei, Kitanaka, Chifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053629/ https://www.ncbi.nlm.nih.gov/pubmed/27027242 http://dx.doi.org/10.18632/oncotarget.8395

Ejemplares similares

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
por: Okada, Masashi, et al.
Publicado: (2017)

Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
por: Takeda, Hiroyuki, et al.
Publicado: (2017)

Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction
por: Kuramoto, Kenta, et al.
Publicado: (2017)

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
por: Suzuki, Shuhei, et al.
Publicado: (2014)

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014)

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014)

Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
por: Suzuki, Shuhei, et al.
Publicado: (2018)

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021)

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
por: Matsuda, Ken-ichiro, et al.
Publicado: (2012)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
por: Sanomachi, Tomomi, et al.
Publicado: (2019)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2021)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression()
por: Li, Zhenghong, et al.
Publicado: (2020)

Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties
por: Kuramoto, Kenta, et al.
Publicado: (2021)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts
por: Okada, Masashi, et al.
Publicado: (2021)

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties
por: Okada, Masashi, et al.
Publicado: (2022)

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)

Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature
por: Nakamura, Fumihiro, et al.
Publicado: (2019)

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer
por: Ito, Tomomichi, et al.
Publicado: (2018)

AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes
por: Zhang, Shuai, et al.
Publicado: (2021)

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2018)

Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2021)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
por: Kuwata, Hitoshi, et al.
Publicado: (2017)

Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma
por: Idei, Urara, et al.
Publicado: (2023)

Pedicled gastric seromuscular patch for one-stage closure of a bronchopleural fistula: a case report
por: Suzuki, Jun, et al.
Publicado: (2018)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

ERK2 and JNK1 contribute to TNF-α-induced IL-8 expression in synovial fibroblasts
por: Namba, Shinichi, et al.
Publicado: (2017)

xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma
por: Sugiyama, Akiko, et al.
Publicado: (2020)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

High‐Throughput Approaches in Carbohydrate‐Active Enzymology: Glycosidase and Glycosyl Transferase Inhibitors, Evolution, and Discovery
por: Chao, Lemeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h731oq4i8e13qhl3jspjamuji1